Hakan Doğruel

Hakan Doğruel

Auto-generated profile, based on publicly available information

Hakan Doğruel

Antalya City Hospital, Clinic of Internal Medicine, Division of Endocrinology and Metabolism, Antalya, Türkiye

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2022 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
HDHakan Doğruel
Hakan Doğruel
HAHatice Tülüce Atlım
Hatice Tülüce Atlım
MAMustafa Aydemir
Mustafa Aydemir
NYNusret Yilmaz
Nusret Yilmaz
RSRAMAZAN SARI
RAMAZAN SARI

24 April 2026 in Obesity Facts
Verified
Journal Article
Open access
SHSema Hepsen
Sema Hepsen
CHCem Haymana
Cem Haymana
GKGizem Ertepe Küçükgöde
Gizem Ertepe Küçükgöde
BÖBüşra Özcan
Büşra Özcan
BÖBurak Özbaş
Burak Özbaş
ASAlper Sönmez
Alper Sönmez
Background: Real-world data directly comparing the safety, tolerability, and effectiveness of semaglutide and tirzepatide in patients with obesity remain limited. This nationwide multicenter observational study compared short-term adverse events, treatment discontinuation, body weight loss (BWL), and metabolic outcomes between the two treatments. Methods: This study included 2,549 patients with obesity treated with semaglutide (n=1,434) or tirzepatide (n=1,115). Adverse events, including time to onset, dose at occurrence, and related discontinuation, were evaluated. Changes in BWL and metabolic parameters up to 6 months were assessed. Subgroup analyses were performed in patients with and without type 2 diabetes mellitus (T2DM). Results: At least one adverse event occurred in 50.9% in the semaglutide group and 51.0% in the tirzepatide group (p=0.524), with gastrointestinal events the most frequently reported. Overall adverse event rates were comparable between groups; however, musculoskeletal and allergic reactions were more common in the tirzepatide group. The onset of gastrointestinal, neuropsychiatric, musculoskeletal symptoms, and hypoglycemia occurred earlier in the tirzepatide group. Discontinuation due to adverse events was similar between groups, except for pancreatic events, which were more frequent in the semaglutide group (p=0.006). Tirzepatide was associated with greater early BWL at all time points. At 6 months, median percentage BWL was 12.6% with semaglutide and 14.4% with tirzepatide. HbA1c reductions were comparable between groups in patients with T2DM. Conclusion: In real-world clinical practice, semaglutide and tirzepatide show similar short-term tolerability and treatment persistence, although tirzepatide is associated with a higher incidence of musculoskeletal and allergic reactions and greater early BWL.

25 January 2024 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
HDHakan Doğruel
Hakan Doğruel
MAMustafa Aydemir
Mustafa Aydemir
NYNusret Yilmaz
Nusret Yilmaz
RSRAMAZAN SARI
RAMAZAN SARI

3 April 2023 in Akdeniz Medical Journal
Verified
Journal Article
Open access
HDHakan Doğruel
Hakan Doğruel
FBFeyza Bora
Feyza Bora
FEFettah Fevzi Ersoy
Fettah Fevzi Ersoy
Amaç: Kronik böbrek hastalığı (KBH) ve proteinürisi olanlarda artmış oksidatif stres ve inflamasyonun kardiyovasküler morbidite ve mortalite ile ilişkili olduğu gösterilmiştir. Vitamin D’nin (VD) organizmada birçok rolünün olduğu son yıllarda VD reseptörünün çok sayıda dokuda gösterilmesiyle anlaşılmıştır. Bu çalışmada KBH olan bireylerde VD düzeyinin, inflamatuvar parametreler ve proteinüri ile ilişkisini değerlendirmeyi amaçladık. Gereç-Yöntem: Çalışmaya nefroloji polikliniğinde takip edilen ve henüz renal replasman tedavisi almamış, evre 3-5 KBH hastalar arasından dahil etme kriterlerini karşılayan 314 hasta alındı. Katılımcıların verileri retrospektif ve kesitsel olarak incelendi. Demografik özellikleri, kreatinin, tahmini glomerüler filtrasyon hızı (t GFH), serum 25(OH)D3, kalsiyum, albümin, fosfor, parathormon (PTH), spot idrarda protein/kreatinin oranı, nötrofil, lenfosit, platelet, nötrofil/lenfosit oranı (NLO) ve platelet/lenfosit oranı (PLO) kaydedildi. Serum 25(OH)D3 düzeyine göre; VD eksikliği olanlar, (29 ng/ml) olmak üzere 3 grup oluşturuldu. Gruplar, inflamatuvar parametreler ve proteinüri düzeyi yönünden karşılaştırıldı. Analizler SPSS 23.0 programı ile yapıldı. Bulgular: VD grupları arasında inflamatuvar parametreler (CRP, NLO ve PLO) açısından fark saptanmadı. Spot idrarda protein/kreatinin oranı VD eksikliği olanlarda, hem VD yetersizliği olanlardan (p:0, 007) hem de VD düzeyi normal olanlardan (p: 0,001) daha yüksekti. Ayrıca yapılan korelasyon analizinde VD düzeyi ile proteinüri arasında negative korelasyon saptandı (r: -267, p: <0,01). Nefrotik düzeyin altında proteinürisi olan bireylerde de VD düzeyi ve proteinüri ilişkisinin korunduğu saptandı (p: 0,018). Sonuç: Proteinüri düzeyinin, VD düzeyi ile negatif korelasyon gösterdiği ve VD eksikliği olanlarda daha yüksek değerlere ulaştığı görüldü. Bu noktada renal ve kardiyovasküler açıdan önemli bir faktör olan proteinürinin azaltılması noktasında VD’nin rolü gündeme gelebilir. Objective: It has been demonstrated that increased oxidative stress and inflammation are associated with increased cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD) and proteinuria. In recent years, it has been understood that vitamin D (VD) has many roles, with the demonstration of the VD receptor in many tissues. In this study, we aimed to evaluate the association of VD level with inflammatory parameters and proteinuria in individuals with CKD. Method: The study included 314 patients who were followed up in the nephrology outpatient clinic with the diagnosis of CKD, had not received renal replacement therapy yet and met the inclusion criteria. The data of the participants were analyzed retrospectively and cross-sectionally. Demographic characteristics, creatinine, estimated glomerular filtration rate, serum 25(OH)D3, calcium, albumin, phosphorus, parathormone (PTH), spot urine protein/creatinine ratio, neutrophil, lymphocyte, platelet, neutrophil/lymphocyte ratio (NLR) and platelet /lymphocyte ratio (PLR) were recorded. According to serum 25(OH)D3 level; Three groups were formed those with VD deficiency (29 ng/ml). The groups were compared in terms of inflammatory parameters and proteinuria levels. Analyzes were performed by using the SPSS 23.0 program. Results: There was no difference between the VD groups in terms of inflammatory parameters (CRP, NLR, and PLR). The protein/creatinine ratio in spot urine was higher in patients with VD deficiency than both those with VD insufficiency (p:0.007) and those with normal VD levels (p:0.001). In addition, a negative correlation was found between VD level and proteinuria (r: -267, p: <0.01). It was found that the association between VD level and proteinuria was preserved in individuals with proteinuria below the nephrotic level (p: 0.018). Conclusion: It was observed that the proteinuria level was negatively correlated with the VD level and reached higher values in those with VD deficiency. At this point, the role of VD in reducing proteinuria, which is an important factor in renal and cardiovascular terms, may become a current issue.

1 January 2026 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
HDHakan Doğruel
Hakan Doğruel
EKElif Nur Karaoğlu
Elif Nur Karaoğlu
NYNusret Yilmaz
Nusret Yilmaz
MAMustafa Aydemir
Mustafa Aydemir
HCHasan Calis
Hasan Calis
RSRAMAZAN SARI
RAMAZAN SARI
Objective: We aimed to evaluate temporal changes in the diagnostic performance of thyroid fine-needle aspiration biopsy (FNAB) over a 15-year period in a single-center, surgically confirmed cohort. Subjects and methods: We retrospectively analyzed thyroid FNABs performed between 2009 and 2023, dividing the data into two intervals (Group 1: 2009–2014; Group 2: 2015–2023). All specimens were interpreted by the same two experienced cytopathologists. Sensitivity, specificity, and Youden’s J were calculated at four diagnostic thresholds (≥AUS/FLUS, ≥FN/SFN, ≥SM, and malignant only), [...] ABSTRACT Objective: We aimed to evaluate temporal changes in the diagnostic performance of thyroid fine-needle aspiration biopsy (FNAB) over a 15-year period in a single-center, surgically confirmed cohort. Subjects and methods: We retrospectively analyzed thyroid FNABs performed between 2009 and 2023, dividing the data into two intervals (Group 1: 2009–2014; Group 2: 2015–2023). All specimens were interpreted by the same two experienced cytopathologists. Sensitivity, specificity, and Youden’s J were calculated at four diagnostic thresholds (≥AUS/FLUS, ≥FN/SFN, ≥SM, and malignant only),